| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PKCi |
| Uniprot No | P41743 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-596aa |
| 氨基酸序列 | PTQRDSSTM SHTVAGGGSG DHSHQVRVKA YYRGDIMITH FEPSISFEGL CNEVRDMCSF DNEQLFTMKW IDEEGDPCTV SSQLELEEAF RLYELNKDSE LLIHVFPCVP ERPGMPCPGE DKSIYRRGAR RWRKLYCANG HTFQAKRFNR RAHCAICTDR IWGLGRQGYK CINCKLLVHK KCHKLVTIEC GRHSLPQEPV MPMDQSSMHS DHAQTVIPYN PSSHESLDQV GEEKEAMNTR ESGKASSSLG LQDFDLLRVI GRGSYAKVLL VRLKKTDRIY AMKVVKKELV NDDEDIDWVQ TEKHVFEQAS NHPFLVGLHS CFQTESRLFF VIEYVNGGDL MFHMQRQRKL PEEHARFYSA EISLALNYLH ERGIIYRDLK LDNVLLDSEG HIKLTDYGMC KEGLRPGDTT STFCGTPNYI APEILRGEDY GFSVDWWALG VLMFEMMAGR SPFDIVGSSD NPDQNTEDYL FQVILEKQIR IPRSLSVKAA SVLKSFLNKD PKERLGCHPQ TGFADIQGHP FFRNVDWDMM EQKQVVPPFK PNISGEFGLD NFDSQFTNEP VQLTPDDDDI VRKIDQSEFE GFEYINPLLM SAEECV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PKCi(Protein Kinase C iota)重组蛋白的3篇文献参考示例(注：文献信息为示例性概括，实际引用时请核实原文信息)：
---
1. **文献名称**：*"Expression and Purification of Active Recombinant PKCι in Baculovirus-Insect Cell System"*
**作者**：Smith J, et al.
**摘要**：本研究利用杆状病毒-昆虫细胞系统成功表达并纯化了具有激酶活性的重组PKCι蛋白，验证了其与底物相互作用的特异性，为后续体外激酶活性分析提供了可靠工具。
---
2. **文献名称**：*"Structural Insights into PKCι Kinase Domain via Recombinant Protein Crystallography"*
**作者**：Lee H, et al.
**摘要**：通过重组PKCι激酶结构域的结晶和X射线衍射分析，揭示了其ATP结合口袋的独特构象，解释了PKCι对特定抑制剂的敏感性差异，为靶向药物设计奠定结构基础。
---
3. **文献名称**：*"Recombinant PKCι Modulates Epithelial-Mesenchymal Transition in Cancer Cells"*
**作者**：Wang Y, et al.
**摘要**：研究证明，外源性重组PKCι蛋白可激活Akt/GSK-3β信号通路，促进肿瘤细胞上皮-间质转化(EMT)，提示PKCι在癌症转移中的潜在调控作用。
---
**提示**：以上为模拟摘要，实际文献需通过PubMed、Google Scholar等平台检索关键词(如“PKCiota recombinant protein”、“PKCι purification”)获取。建议结合具体研究方向补充筛选。
Protein kinase C iota (PKCi), a member of the atypical protein kinase C (aPKC) subfamily, is a serine/threonine kinase involved in diverse cellular processes, including cell polarity, proliferation, and survival. Unlike conventional PKC isoforms, PKCi functions independently of calcium and diacylglycerol, relying instead on protein-protein interactions for activation. It plays critical roles in signaling pathways such as Ras/MAPK and PI3K/Akt, often dysregulated in cancer. PKCi overexpression is linked to tumor aggressiveness, metastasis, and poor prognosis in multiple cancers (e.g., lung, ovarian, glioblastoma), making it a potential therapeutic target.
Structurally, PKCi contains a PB1 domain for scaffold interactions, a C1 domain for membrane binding, and a kinase domain. It interacts with polarity proteins like Par6 to regulate cell polarity and with oncogenic effectors like MEK5. Recombinant PKCi proteins are generated via heterologous expression systems (e.g., E. coli, mammalian cells) to study its biochemical properties, substrate specificity, and inhibitor screening. These recombinant tools enable precise analysis of PKCi’s role in disease mechanisms and drug discovery. Tagged versions (e.g., His-, GST-, or FLAG-tagged) facilitate purification and functional assays. Research using recombinant PKCi has advanced understanding of its dual roles as both an oncogenic driver and tumor suppressor in context-dependent scenarios, highlighting its complex regulatory networks. Ongoing studies aim to develop selective PKCi inhibitors for targeted cancer therapies.
×
